Premium
Intensive chemotherapy with combinations containing anthracyclines for refractory and relapsing multiple myeloma
Author(s) -
Palva I. P.,
Ahrenberg P.,
Harja K. Ala,
Almqvist A.,
Elonen E.,
Hallman H.,
Hänninen A.,
Ilvonen M.,
Isomaa B.,
Jouppila J.,
Järvenpää E.,
Järventie G.,
Kilpi H.,
Koivunen E.,
Kätkä K.,
Kääriäinen M.,
Lahtinen R.,
Laitinen A.,
Lehtinen M.,
Mäkelä H.,
Nyländen P.,
Nyman D.,
Oivanen T.,
Pakkala S.,
Pelliniemi TT.,
Pulli T.,
Rajamäki A.,
Ruutu T.,
Savola J.,
Soininen K.,
Timonen T.,
Wasastjerna C.,
Vilpo J.
Publication year - 1990
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.1990.tb00362.x
Subject(s) - vincristine , medicine , epirubicin , doxorubicin , chemotherapy , refractory (planetary science) , dexamethasone , oncology , anthracycline , multiple myeloma , cyclophosphamide , gastroenterology , cancer , breast cancer , physics , astrobiology
94 patients with refractory multiple myeloma were treated in a multicentre trial with combinations of cytotoxic drugs including anthracyclines. All were refractory to a 5‐drug combination containing 3 alkylating agents, vincristine and methylprednisolone (MOCCA). With a combination of epirubicin and iphosphamide a 50% response was achieved in 9% of 22 patients. The response rate after schedule VAP (vincristine, doxorubicin and prednisolone) was 8% of 13 patients and that after schedule VAD (vincristine, doxorubicin and dexamethasone) 20% of 59 patients. The previous chemotherapy had lasted for less than 12 months in 13 cases from among all these patients, and 5 of these (38%) responded. In contrast, there were only 10 responders (12%) among the 81 patients with longer previous chemotherapy.